Wingate Wealth Advisors Inc. Acquires Shares of 75 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Wingate Wealth Advisors Inc. acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 75 shares of the biopharmaceutical company’s stock, valued at approximately $53,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. International Assets Investment Management LLC raised its position in shares of Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after buying an additional 879,916 shares during the last quarter. Worldquant Millennium Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $127,489,000. KBC Group NV raised its position in shares of Regeneron Pharmaceuticals by 296.7% in the fourth quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock valued at $97,338,000 after buying an additional 102,198 shares during the last quarter. Icon Wealth Advisors LLC raised its position in shares of Regeneron Pharmaceuticals by 18,342.0% in the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock valued at $79,874,000 after buying an additional 75,569 shares during the last quarter. Finally, State Street Corp increased its position in Regeneron Pharmaceuticals by 1.3% during the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after purchasing an additional 61,277 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Down 2.8 %

NASDAQ REGN opened at $690.36 on Tuesday. The firm has a 50 day simple moving average of $715.81 and a 200-day simple moving average of $909.02. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20. The firm has a market cap of $75.86 billion, a price-to-earnings ratio of 18.03, a PEG ratio of 2.38 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the previous year, the firm earned $11.86 earnings per share. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.51%.

Wall Street Analyst Weigh In

REGN has been the subject of several recent analyst reports. JPMorgan Chase & Co. cut their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Sanford C. Bernstein cut their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Evercore ISI cut their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Finally, Morgan Stanley cut their price objective on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.